古鰲科技(300551.SZ)及子公司年初至今共取得91項專利證書
格隆匯12月31日丨古鰲科技(300551.SZ)公佈,自2019年1月1日至公告披露日期間,公司及全資子公司崑山古鰲電子機械有限公司(“崑山古鰲”)共收到了中華人民共和國國家知識產權局頒發的4項發明專利證書,78項實用新型專利證書,9項外觀設計專利證書。
截止公告披露日,公司及崑山古鰲共擁有發明專利133項,實用新型專利421項,外觀設計專利48項。上述專利所涉及技術與公司主要技術相關,將應用於公司相關業務中。上述專利的取得不會對公司近期生產經營產生重大影響,但有利於公司進一步完善知識產權保護體系,發揮自主知識產權優勢,並形成持續創新機制,保持技術領先地位,提升公司的核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.